Zacks Investment Research Downgrades INDIVIOR PLC/S (OTCMKTS:INVVY) to Hold

INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

INVVY stock opened at $3.30 on Wednesday. The company has a market capitalization of $480.68 million, a PE ratio of 2.00 and a beta of -0.20. INDIVIOR PLC/S has a 12-month low of $1.98 and a 12-month high of $7.74. The business’s fifty day moving average price is $2.58 and its 200 day moving average price is $2.95.

INDIVIOR PLC/S Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Further Reading: Treasury Bonds

Get a free copy of the Zacks research report on INDIVIOR PLC/S (INVVY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.